A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
Clinical trial NCT02644967 · COMPLETED
Trial details
- NCT number
- NCT02644967
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2020-02-01
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.